Inpharma 1381 - 5 Apr 2003

1

■ PA 457* selectively blocks the last step of HIV maturation, resulting in noninfectious HIV particles, according to an update on the drug’s development presented at the 4th International Antiviral Drug Discovery and Development Summit, held recently in Princeton, US. According to the update, PA 457, which is the first of a new class of HIV drugs called maturation inhibitors, has demonstrated potent activity against HIV strains resistant to currently available drugs. Furthermore, PA 457 appears to have synergistic action with approved HIV drugs. In vitro metabolism studies suggest that PA 457 does not significantly interact with other antiretroviral agents. Preclinical safety tests are ongoing and have provided promising preliminary results. Panacos Pharmaceuticals plans to file an investigational new drug application later this year to initiate human clinical trials of PA 457. * Panacos Pharmaceuticals; preclinical Panacos Pharmaceuticals Inc. Panacos Pharmaceuticals Reports Development Progress on its HIV Drug Candidate PA-457 at Antiviral Drug Summit. Media Release : 26 Mar 2003. Available from: URL: http:// 809019460 www.panacos.com

1173-8324/10/1381-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Inpharma 5 Apr 2003 No. 1381